Please login to the form below

Not currently logged in
Email:
Password:

Sue Mahony to retire as president of Lilly Oncology

She will continue in her position until August 31

Eli LillyEli Lilly’s senior vice president and president of Lilly Oncology, Sue Mahony, is set to retire at the end of August after 18 years of service with the company.

Mahony led Lilly Oncology through the integration of ImClone and launched several brands including Verzenio.

She also most recently led the refocusing of the company’s oncology R&D strategy.

Prior to this, as senior vice president of human resources and diversity, Mahony played in a role in restructuring the company into business units.

She said: “What I’ve appreciated over the years is the opportunity to participate in something greater than myself.

“We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”

Prior to her time with Eli Lilly, Mahony has served in various roles for Amgen, Bristol-Myers Squibb and Schering-Plough.

Lilly has said it is considering internal and external candidates to find Mahony’s successor.

5th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...

Infographics